Related Experiment Video
Updated: Oct 26, 2025

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
Published on: March 17, 2012
Towards personalized medicine for amyotrophic lateral sclerosis
Julien Cassereau1, Philippe Corcia2, Pascal Reynier3
1Department of Neurology, University Hospital, Angers, France; Amyotrophic Lateral Sclerosis (ALS) Center, University Hospital, Angers, France; University of Angers, Institut National de la Santé et de la Recherche Médicale (INSERM) and Centre National de la Recherche Scientifique (CNRS) Mitochondrial and Cardiovascular Physiopathology (MitoVasc) Institute, Angers, France.
Abstract:
Mohassel et al. provide unprecedented dichotomy of consequences on sphingolipid biosynthesis between pathogenic variants in the SPTLC1 gene, responsible for either amyotrophic lateral sclerosis (ALS) or hereditary sensory and autonomic neuropathy type 1 (HSAN1). Normalization of sphingolipid levels by siRNA selectively targeting the ALS mutant allele mRNA sheds light on new therapeutic approaches.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Satellite Stem Cells and Muscular Dystrophy
Alzheimer's Disease: Treatment
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

